CRSP
Price
$48.63
Change
+$1.14 (+2.40%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
4.1B
42 days until earnings call
DNLI
Price
$14.32
Change
+$0.22 (+1.56%)
Updated
Jun 30, 12:58 PM (EDT)
Capitalization
2.05B
31 days until earnings call
Interact to see
Advertisement

CRSP vs DNLI

Header iconCRSP vs DNLI Comparison
Open Charts CRSP vs DNLIBanner chart's image
CRISPR Therapeutics AG
Price$48.63
Change+$1.14 (+2.40%)
Volume$60.13K
Capitalization4.1B
Denali Therapeutics
Price$14.32
Change+$0.22 (+1.56%)
Volume$2.12K
Capitalization2.05B
CRSP vs DNLI Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. DNLI commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and DNLI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CRSP: $47.49 vs. DNLI: $14.10)
Brand notoriety: CRSP and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 592% vs. DNLI: 280%
Market capitalization -- CRSP: $4.1B vs. DNLI: $2.05B
CRSP [@Biotechnology] is valued at $4.1B. DNLI’s [@Biotechnology] market capitalization is $2.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, CRSP is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while DNLI’s TA Score has 2 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 4 bearish.
  • DNLI’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than DNLI.

Price Growth

CRSP (@Biotechnology) experienced а +7.32% price change this week, while DNLI (@Biotechnology) price change was +1.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.84%, and the average quarterly price growth was +6.72%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.1B) has a higher market cap than DNLI($2.05B). CRSP YTD gains are higher at: 20.655 vs. DNLI (-30.815). CRSP has higher annual earnings (EBITDA): -455.24M vs. DNLI (-505.16M). CRSP has more cash in the bank: 1.86B vs. DNLI (818M). DNLI has less debt than CRSP: DNLI (48.6M) vs CRSP (219M). CRSP has higher revenues than DNLI: CRSP (35M) vs DNLI (0).
CRSPDNLICRSP / DNLI
Capitalization4.1B2.05B200%
EBITDA-455.24M-505.16M90%
Gain YTD20.655-30.815-67%
P/E RatioN/AN/A-
Revenue35M0-
Total Cash1.86B818M227%
Total Debt219M48.6M451%
FUNDAMENTALS RATINGS
CRSP vs DNLI: Fundamental Ratings
CRSP
DNLI
OUTLOOK RATING
1..100
4250
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
4163
P/E GROWTH RATING
1..100
7999
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (67) in the Biotechnology industry is in the same range as DNLI (93). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as DNLI (94). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

CRSP's Price Growth Rating (41) in the Biotechnology industry is in the same range as DNLI (63). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

CRSP's P/E Growth Rating (79) in the Biotechnology industry is in the same range as DNLI (99). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPDNLI
RSI
ODDS (%)
Bearish Trend 4 days ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
75%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 19 days ago
84%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
82%
Aroon
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CGXU27.350.17
+0.63%
Capital Group International Focus Eq ETF
AMJB30.490.17
+0.56%
Alerian MLP Index ETN
EZM61.790.17
+0.28%
WisdomTree U.S. MidCap Earnings ETF
SKRE11.830.03
+0.25%
Tuttle Cptl Dl 2X Invrs Rgnl Banks ETF
BTAL17.61-0.11
-0.62%
AGF U.S. Market Neutral Anti-Beta

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-2.69%
NRIX - DNLI
57%
Loosely correlated
-1.69%
BEAM - DNLI
56%
Loosely correlated
-1.98%
OCUL - DNLI
55%
Loosely correlated
-2.54%
RGNX - DNLI
55%
Loosely correlated
-4.11%
ABCL - DNLI
54%
Loosely correlated
-3.48%
More